Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06985342 · ClinicalTrials.gov registry record · Phase 4
Acute Migraine Treatment in the ED With Gepants
A Phase 4 study of Migraine Headaches, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06985342 is a Phase 4 study of Migraine Headaches that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 100 participants, below the 111-participant average among 4 other Migraine Headaches trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06985342, a Phase 4 study of Migraine Headaches, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.
Conditions Studied
Interventions
- DRUG Rimegepant
- DRUG Zavegepant
Study Locations (1)
New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2026-10-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06985342
The ClinicalTrials.gov registry entry for NCT06985342 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 111-participant average among 4 other Migraine Headaches trials with a reported enrollment target (10% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine Headaches appearing as the primary indexed condition, and to 2 interventions - of which Rimegepant is the first listed.
NCT06985342 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06985342 about?
NCT06985342 is a clinical study titled "Acute Migraine Treatment in the ED With Gepants". This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor...
What is the current status of trial NCT06985342?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-06-05. Estimated completion is 2026-10-30.
What conditions does trial NCT06985342 study?
This clinical trial studies the following conditions: Migraine Headaches.
What interventions are being tested in trial NCT06985342?
The interventions under investigation include: Rimegepant (DRUG), Zavegepant (DRUG).
Who is sponsoring clinical trial NCT06985342?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06985342 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Headaches
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
COMPLETED · Phase 2
-
Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
COMPLETED · Phase 1
-
Set Point Acupuncture for Migraines Using a Digital Assistant
COMPLETED · Phase 1
-
The Utility of Telemedicine in the Management of Migraine
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.